Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 December, 2018 13:40 IST
Suven Life Sciences secures 2 overseas product patents
Source: IRIS | 17 May, 2018, 11.03AM
Comments  |  Post Comment

Suven Life Sciences announces today that the grant of two product patents from Australia and one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

The granted claims of the patents include the class of selective H3 Inverse agonists and 5HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company declined Rs 3.05, or 1.59%, to trade at Rs 188.65. The total volume of shares traded was 28,852 at the BSE (10.49 a.m., Thursday).





Suven Life Sciences Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Commercial Engineers & Body Builders Company wins order worth Rs 1.52 bn - 19-Dec-2018 10:51
Glenmark Pharmaceuticals forays into branded dermatology segment in U.S. - 19-Dec-2018 10:33
M&M to hike stake in associate company Sampo Rosenlew - 18-Dec-2018 10:37
Glenmark Pharma gets nod for Fluocinolone Acetonide oil - 18-Dec-2018 10:08
BGR Energy Systems bags order worth Rs 494 mn from Tamilnadu Transmission Corp - 18-Dec-2018 10:04
Lupin receives approval from USFDA for Clobazam tablets - 18-Dec-2018 10:01
Ahluwalia Contracts (India) secures new order worth RS 4.25 bn - 17-Dec-2018 15:31
Lupin receives tentative USFDA approval for Tadalafil tablets - 17-Dec-2018 14:49
Gayatri Projects bags new order worth Rs 4.93 bn - 17-Dec-2018 09:43
Zydus Cadila receives USFDA approvals for two drugs - 17-Dec-2018 09:39
Biocon's API manufacturing facility completes USFDA inspection - 17-Dec-2018 09:36
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer